| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | silmitasertib | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.064 | 0.8 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | SN-38 | GDSC1000 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | OSI-027 | GDSC1000 | pan-cancer | AAC | 0.0093 | 0.8 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.0087 | 0.8 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | -0.057 | 0.8 |